Diagnostic and Therapeutic Radiopharmaceutical Agents for Selective Discrimination of Prostate Cancer
Final rept. 1 Oct 2005-30 Sep 2009
WASHINGTON STATE UNIV PULLMAN
Pagination or Media Count:
The project investigated the development of ligand linked Flutamide analogs for complexing MCO3 Re,99mTc organometallic species to target prostate cancer. The project has been successful in developing and testing new synthetic strategies for this application. General methods were established for preparing the cold Re and 99mTc complexes in excellent yields95 at 10-4,10-5 M ligand concentration, testing the stability of the complexes pH, temperature and in vitro serum, AR - prostate cancer cells. Several 99mTc flutamide analogs were examined. Tridentate ligands i.e., cysteine, histidine, dipyridylamine, iminodiacetic acid were successfully prepared and maintained stability in vitro. The 21 approach analogs were prepared, however, failed to maintain the complex conformation, when examined under biological conditions. Second generation compounds based on the initial experiments with addition functional group are currently being investigated.
- Medicine and Medical Research